“The power of AI isn’t about making drugs faster,” said Abraham Heifets, CEO of Atomwise, Inc., an AI-enabled drug discovery company headquartered in San Francisco. “If you approach a big pharma and you are going to be fifth-in-class and undifferentiated, and through the power of AI, we can make you fourth-in-class and undifferentiated, that's a failure from a business point of view, it's a failure strategically and it's a failure for patients.”
However, the bar for AI seems to be low. Heifets said he has far more conversations around the ability of...
